Outset Medical, Inc. (NASDAQ:OM – Get Free Report) has earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $4.64.
A number of research analysts recently commented on OM shares. Royal Bank of Canada downgraded Outset Medical from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $6.00 to $3.00 in a research note on Thursday, August 8th. TD Cowen lowered their target price on Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 8th.
Read Our Latest Research Report on OM
Insider Transactions at Outset Medical
Institutional Trading of Outset Medical
Several institutional investors have recently added to or reduced their stakes in OM. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Outset Medical during the 2nd quarter worth approximately $259,000. Squarepoint Ops LLC raised its position in shares of Outset Medical by 74.1% during the second quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock worth $309,000 after purchasing an additional 34,187 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of Outset Medical by 228.3% during the second quarter. Cubist Systematic Strategies LLC now owns 200,939 shares of the company’s stock worth $774,000 after purchasing an additional 139,740 shares during the period. Marshall Wace LLP raised its position in shares of Outset Medical by 487.8% during the second quarter. Marshall Wace LLP now owns 314,187 shares of the company’s stock worth $1,210,000 after purchasing an additional 260,740 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Outset Medical during the second quarter worth approximately $49,000.
Outset Medical Stock Down 4.3 %
OM stock opened at $0.83 on Thursday. The company has a market cap of $43.08 million, a PE ratio of -0.25 and a beta of 2.00. The business has a 50-day simple moving average of $3.63 and a 200 day simple moving average of $3.19. Outset Medical has a 52 week low of $0.82 and a 52 week high of $16.13. The company has a quick ratio of 5.32, a current ratio of 6.42 and a debt-to-equity ratio of 2.11.
About Outset Medical
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Read More
- Five stocks we like better than Outset Medical
- Transportation Stocks Investing
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Calculate Return on Investment (ROI)
- 3 Stocks That Could Beat the September Blues
- The Most Important Warren Buffett Stock for Investors: His Own
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.